Total Funding
57
53
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
220607
Phaxiam develops bacteriophage-based therapies to combat antimicrobial resistance in bacterial infections.
About the Company
Phaxiam is a clinical-stage biopharmaceutical company focused on developing innovative bacteriophage-based therapies to combat antimicrobial resistance. Specializing in the field of phage therapy, Phaxiam's research and development efforts are aimed at creating antibacterial treatments that utilize bacteriophage viruses, or phages, to target
and eliminate resistant bacterial infections in humans. These infections are a growing concern in healthcare due to their ability to resist traditional antibiotics. By harnessing the specificity and effectiveness of phages, Phaxiam is working towards providing new solutions for serious bacterial infections that are difficult to treat with existing antibiotics.
